GLP-1 Market
LLY $1170.14 ▲ +0.5% NVO $39.40 ▼ -1.0% PFE $27.93 ▲ +0.7% VKTX $40.85 ▲ +35.7% KLRA $12.79 ▲ +6.7% GPCR $36.91 ▲ +0.3% RHHBY $55.56 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Solbinsiran

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Solbinsiran and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07269210

    A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

    Not yet reported Eli Lilly and Company 60 participants Est. completion 2027-08 41 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT04644809

    A Study of LY3561774 in Participants With Dyslipidemia

    Not yet reported Eli Lilly and Company 74 participants Est. completion 2022-05-17 5 sites Stand-alone
    Other conditions: Dyslipidemias
    View official trial listing →
  • Completed NCT NCT05256654

    A Study of LY3561774 in Participants With Mixed Dyslipidemia

    Not yet reported Eli Lilly and Company 205 participants Est. completion 2024-05-23 41 sites Stand-alone
    Other conditions: Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Solbinsiran, LY3561774

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.